Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
Status: Open
- Who can apply
- Nonprofits, small businesses, state, local and tribal governments, tribes, schools and universities, for-profit companies, others.
- Deadline
- Thursday, January 7, 2027 - check the notice for the exact time
- Opened Nov 18, 2024
- Amount
- Not stated by the source
- Official source
- Read and apply at the official source Found on grants.gov
- Requirements
- Documents with the official notice: PAR-25-070-Full-Announcement.html
- Organizations need a SAM.gov ID number (UEI) to apply. Individuals do not.
- Application fee
- We do not read fees from notices; check the official notice. GrantsWindow never charges you.
- Funder
- National Institutes of Health (federal)
- Assistance Listing 93.393
- Last checked
- Checked Nov 15, 2026 at the official source
From the official notice
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented ...
Topics this may fit (our guess)
minority-serving